According to a new research review published in Frontiers in Pharmacology, CBD produces various therapeutic benefits against Alzheimer's disease. Australian researchers were prompted to review articles that had previously investigated CBD's effects on the disease because they were intrigued by the compound's neuroprotective, anti-inflammatory, and antioxidant properties, all of which could reduce or inhibit the cognitive and functional impairment resulting from Alzheimer's. Some of the in vivo studies reviewed suggested CBD reduced reactive gliosis and the neuroinflammatory response, something that has been linked to neurodegeneration in Alzheimer's. CBD may also promote neurogenesis to reduce deterioration of cognitive functions. Preclinical animal studies suggested CBD reverses and prevents cognitive deficits from developing. Other studies found CBD's effects are further enhanced by THC, and that a combination offers greater anti-dementia effects without producing the psychoactive effects that THC alone would produce.
The review concludes, “The studies reviewed in this mini review provide “proof of principle” for the therapeutic benefits CBD and possibly CBD-THC combinations pose for AD therapy... The studies discussed here provide promising preliminary data and the translation of this preclinical work into the clinical setting could be realized relatively quickly: CBD is readily available, appears to only have limited side effects and is safe for human use.”